Core Viewpoint - Cancer is a significant global public health challenge, with the WHO reporting 10 million deaths in 2020, accounting for 1/6 of total deaths, and projections indicating that without urgent action, cancer deaths could exceed 18 million by 2050 [3][4]. Group 1: Current State of Cancer Research - China has emerged as a key player in global cancer research, with a record number of studies presented at major international oncology conferences, including 60 studies at the ESMO Asia Congress 2025 and 73 at the ASCO annual meeting [3]. - The National Healthcare Security Administration has added 36 cancer drugs to the 2025 basic medical insurance catalog, representing 31.58% of the new additions, thereby expanding treatment options for cancer patients [3]. Group 2: Future Outlook on Cancer Management - Experts predict that within the next 25 years, cancer will be recognized as a controllable chronic disease, with significant advancements in theoretical and technological innovations required to achieve this goal [4][5]. - The global burden of cancer is expected to rise, with an estimated 28.4 million new cases by 2040, a 47% increase from 19.3 million in 2020 [6]. Group 3: Factors Influencing Cancer Development - Five main factors contributing to cancer development have been identified: external triggers, infection-related factors, hormonal/receptor abnormalities, lifestyle-related factors, and psychological and immune-related triggers [7]. - The essence of cancer is a disruption in the body's regulatory mechanisms, leading to uncontrolled cell proliferation, which emphasizes the need for strategies that enhance the body's regulatory capabilities [7]. Group 4: Innovations in Cancer Treatment - The integration of advanced technologies such as AI, genomics, and precision medicine is expected to improve cancer survival rates significantly [8]. - A new classification standard for cancer is anticipated to revolutionize management and treatment, promoting a collaborative approach across multiple disciplines [8]. Group 5: Challenges Ahead - The transition from fragmented to integrated treatment poses challenges, including the urgent need for knowledge updates among healthcare professionals and the development of innovative diagnostic and treatment technologies [10]. - Early diagnosis is crucial for improving treatment success rates, with AI playing a role in enhancing the identification of high-risk populations and optimizing screening processes [10]. Group 6: Immunotherapy as a Growth Area - Immunotherapy has emerged as a significant growth area in cancer treatment, with a projected compound annual growth rate of 177.4% from 2017 to 2023, potentially reaching a global market size of $84.9 billion by 2030 [11]. - Despite its early development stage, immunotherapy shows great promise, but challenges remain in biomarker selection, toxicity management, and cost control [11].

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The cell therapy industry is a precision medicine strategy that involves the infusion of modified or expanded cells to treat diseases or repair tissues, leveraging the inherent functions and plasticity of cells to intervene in disease mechanisms [2] - Immune cell therapy is categorized into two main systems: immune cell therapy and stem cell therapy, with CAR-T, TCR-T, and NK cell therapies being the core focus due to their advanced technology and dense global research pipelines [3] Summary by Sections Cell Therapy Logic - Cell therapy involves using autologous or allogeneic cell materials that are modified and reintroduced into patients to combat diseases or repair tissues [2] Immune Cell Therapy Classification - Immune cell therapy is divided into CAR-T therapy, TCR-T therapy, and NK cell therapy, among others, with CAR-T therapy being the most prominent due to its technological maturity and extensive research pipeline [3] CAR-T Therapy Advantages - CAR-T therapy allows T cells to recognize and eliminate tumor cells without being restricted by MHC expression levels, making it particularly effective for hematological malignancies [9][10] - The therapy targets specific proteins such as CD19, BCMA, and CD22, with ongoing research expanding into solid tumors [11] TCR-T Therapy Advantages - TCR-T therapy can recognize a broader range of antigens, including intracellular ones, thus providing an advantage in targeting complex tumor types [15][16] - It is particularly effective against various solid tumors, with ongoing research focusing on multiple target antigens [17] Global Solid Tumor Incidence and Market Size - The number of global solid tumor cases is projected to increase from 16.5 million in 2019 to 19.2 million by 2024, with a compound annual growth rate (CAGR) of 2.8% [22] - The market for immune cell therapy targeting solid tumors is expected to grow from $1.19 billion in 2019 to $4.35 billion by 2024, with a CAGR of 29.6% [25] Non-Solid Tumor Treatment Market - The market for immune cell therapies targeting non-tumor diseases, such as autoimmune diseases and viral infections, is projected to reach $1.36 billion by 2030, with a CAGR of 83.9% from 2027 to 2030 [32]

Core Insights - The report highlights the rapid growth and potential of the tumor immune cell therapy industry, which is seen as a key breakthrough in cancer treatment, driven by increasing global cancer challenges and limitations of traditional therapies [3][8][10] - The global market for tumor immune cell therapy is projected to reach $84.9 billion by 2030, with China expected to reach 69.5 billion yuan, reflecting a compound annual growth rate (CAGR) of 177.4% from 2017 to 2023 [3][9][10] Disease Challenges - The global cancer burden is escalating, with over 20 million new cases and nearly 10 million deaths expected in 2024, highlighting the urgent need for more effective and safer treatment options beyond traditional methods [3][8] Technology Principles - Tumor immune cell therapy enhances the body's immune response by modifying immune cells outside the body and reintroducing them to target cancer cells, utilizing technologies such as CAR-T, TCR-T, and NK cell therapies [3][8][9] Market Scale - The industry has entered a high-growth phase since the approval of the first CAR-T cell therapy product in 2017, with significant market expansion anticipated as more therapies receive approval [9][10] Industry Collaboration - There is a collaborative effort among government, enterprises, and research institutions to support the development of the tumor immune cell therapy industry, including policy initiatives to streamline product evaluation and enhance research and development [10]